Editorial Perspectives on Downstream Bioprocessing

1. From BPI West: A Roundtable Discussion On Continuous Manufacturing 4/14/2025

   Process Development experts share their thoughts on continuous manufacturing at this year's BPI West, touching on its benefits and present barriers to adoption.

2. Areas For Advancement In Peptide Manufacturing 2/27/2025

   Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.

3. Cell Therapy Manufacturing Trends And Advancements Continuing In 2025 12/26/2024

   In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.

4. The Path To Producing An Insulin Biosimilar 7/17/2024

   I met with rBIO co-founder and president, Cameron Owen, as well as its CSO, Dr. Deenadayalan Bakthavatsalam, to learn about what it takes to develop an insulin biosimilar. They candidly told me about the company’s plan of execution, as well as how challenging it is to scale-up manufacturing to a commercial level (in the ballpark of several metric tons per year for insulin) — which is the company’s primary focus right now.

5. Improving AAV Purity Upstream With PCL Manufacturing 3/21/2024

   The downstream separation of AAV capsids affects end-product purity and has been identified as a key pain point of the industry. Ultragenyx’s Dennis Huang advises starting with higher-quality yields upstream.

6. Doubling Down On Biopharma's Growing Skills Drought 3/13/2024

   The biopharmaceutical industry is building manufacturing capacity at breakneck speed. According to PhRMA, there are 1,580-and-counting biopharma manufacturing facilities in the U.S. alone. Problem is, we're way short on filling those facilities with skilled labor. NIIMBL wants to change that. Here's how, and a great opportunity for big pharma, biotech sponsors, CDMOs, academics, and more to help.

7. Biomanufacturing Capacity Crunch Part 2: Building Optionality 10/12/2022

   In conference event programming, in the trade press, and in water cooler conversation we’re making too many generalizations—which in turn create misperceptions—about the so-called biopharmaceutical manufacturing “capacity” crunch.

8. Biopharma CMC/Regulatory Relationships In a Global Market 7/27/2022

   Three veteran regulatory/CMC experts dish the good, the bad, and the ugly from the biopharma’s perspective, offering their insight into how you actually can efficiently file and win in multiple global jurisdictions and what mistakes lead to lost time, money, and sanity.

9. Engineering Antibodies To Suppress Severe Allergic Reactions 5/12/2022

   Dr. Jessica Grossman’s life’s work has been dedicated to women’s health, maternal health, family health, and inspiring the advance of female leadership in life sciences. She’s paving that path in her current role as CEO at IgGenix, which is pioneering genomically-engineered antibodies for the treatment of severe allergies.

10. Reengineering Biologics Manufacturing And Access With Spirulina 1/24/2022

    The “democratization” of biologics requires cost, time, and resource elimination from cell culture to administration and every step in between. Here’s how one innovative emerging biotech is leveraging one of the world’s oldest and most prolific organisms to that end.